Skip NavigationSkip to Content
Return Return to Search Results

Identification of Compounds With Preferential Inhibitory Activity Against Low-Nm23-Expressing Human Breast Carcinoma and Melanoma Cell Lines

  1. Author:
    Freije, J. M. P.
    Lawrence, J. A.
    Hollingshead, M. G.
    Delarosa, A.
    Narayanan, V.
    Grever, M.
    Sausville, E. A.
    Paull, K.
    Steeg, P. S.

  2. Author Address

    Steeg PS NCI WOMENS CANC SECT PATHOL LAB DIV CLIN SCI BLDG 10 ROOM 2A33 BETHESDA, MD 20892 USA NCI WOMENS CANC SECT PATHOL LAB DIV CLIN SCI BETHESDA, MD 20892 USA NCI FREDERICK CANC RES & DEV CTR BIOL TESTING BRANCH DEV THERAPEUT PROGRAM FREDERICK, MD 21702 USA NCI DEV THERAPEUT PROGRAM ROCKVILLE, MD 20852 USA
    1. Year: 1997
  2. Journal: Nature Medicine
    1. 3
    2. 4
    3. Pages: 395-401
  4. Type of Article: Article
  1. Abstract:

    We have used the COMPARE computer algorithm and Nm23 expression as a marker of tumor metastatic potential to examine the in vitro antiproliferative activity of chemotherapeutic drugs on human breast carcinoma and melanoma cell lines. None of 171 compounds in clinical use or under development and only 40 of 30,000 repository compounds exhibited preferential growth inhibition of low-Nm23-expressing, metastatically aggressive cell lines with a Pearson correlation coefficient of less than or equal to-0.64. Characterization of one compound, NSC 645306, is presented including in vivo activity in a hollow fiber assay. The data demonstrate a novel approach to drug identification for aggressive human tumors. [References: 40]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel